There are 807 resources available
377P - Aumolertinib as second-line therapy in T790M-positive or-negative patients with EGFR-mutated non-small cell lung cancer (NSCLC): A retrospective study
Presenter: Hongying Lv
Session: Poster viewing 05.
378P - Could the model of EGFR-TKIs plus antiangiogenesis as first-line treatments in patients with EGFR-mutated non-small cell lung cancer take a step further: A updated meta-analysis
Presenter: Yuexiao Qi
Session: Poster viewing 05.
380P - Survival outcome and cost-effectiveness of tyrosine kinase inhibitor in EGFR sensitive mutation advanced-stage NSCLC in Thammasat university hospital
Presenter: Chayanid Rungtivasuwan
Session: Poster viewing 05.
381P - Real-world experience of treatment with afatinib in advanced non-small cell lung cancer (NSCLC) in Vietnam
Presenter: Hiep Dong
Session: Poster viewing 05.
382P - Real-world data on treatment outcome of ALK positive non-small cell lung cancer from an Indian multi-centric cancer registry
Presenter: Soumya Surath Panda
Session: Poster viewing 05.
383P - Treatment outcomes with BRAF inhibitors with or without MEK inhibitors in advanced non-small cell lung cancer with positive BRAF mutation: A systematic review
Presenter: Animesh Saha
Session: Poster viewing 05.
384P - Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)
Presenter: Hiroaki Akamatsu
Session: Poster viewing 05.
385P - Efficacy and safety of pyrotinib in untreated, advanced non-small cell lung cancer with HER2 mutations: A parallel, multi-center, multi-cohort patient-centric study (CTONG1702 and 1705)
Presenter: Si-Yang Liu
Session: Poster viewing 05.
386P - Efficacy of anlotinib in posterior line treatment of locally advanced and metastatic NSCLC with KRAS mutation
Presenter: Xin Li
Session: Poster viewing 05.
387P - Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
Presenter: Hidehito Horinouchi
Session: Poster viewing 05.